Published in Br J Clin Pharmacol on October 31, 2006
Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells. BMC Cancer (2010) 0.82
Immunohistochemical expression of MMP-2 and MMP-8 in oral squamous cell carcinoma. J Clin Exp Dent (2015) 0.75
Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. Neoplasia (2017) 0.75
Matrix metalloproteinases. J Biol Chem (1999) 12.08
Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 8.29
Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet (1990) 5.65
Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev (1995) 1.93
M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res (1993) 1.66
The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol (1992) 1.50
Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst (1993) 1.49
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer (2002) 1.49
Matrix metalloproteinase inhibitors. Invest New Drugs (1997) 1.43
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem (1998) 1.41
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol (2004) 1.29
Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs (2000) 1.12
Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology (2001) 1.05
Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res (1999) 1.00
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol (2005) 0.99
Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. World J Gastroenterol (2005) 0.98
Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest (2003) 0.96
Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther (2004) 0.94
Metalloproteinase inhibitors as therapeutics. Clin Exp Rheumatol (1993) 0.93
Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. Int J Oncol (2002) 0.92
Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg (2001) 0.89
Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res (2002) 0.86
Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation. J Pharmacokinet Biopharm (1983) 0.85
Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. Transplant Proc (2005) 0.83
Risperidone-induced marked elevation of serum creatine kinase in adolescence. A case report. Pharmacopsychiatry (2003) 0.80
Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther (2005) 0.78
Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus. Rheumatol Int (2003) 0.77
Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatry (2005) 1.11
Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis. Mol Pharmacol (2002) 1.07
Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol (2010) 1.05
Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol (2003) 0.95
Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS (2015) 0.92
Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. J Thorac Oncol (2010) 0.91
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J Pharm Sci (2008) 0.89
Effect of a selective inhibitor of secretory phospholipase A2, S-5920/LY315920Na, on experimental acute pancreatitis in rats. J Pharmacol Sci (2004) 0.89
Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment. Pharmacology (2015) 0.89
Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model. J Pharm Sci (2008) 0.88
Translocation of Pseudomonas aeruginosa from the intestinal tract is mediated by the binding of ExoS to an Na,K-ATPase regulator, FXYD3. Infect Immun (2010) 0.86
Assessment of pharmacy students' communication competence using the Roter Interaction Analysis System during objective structured clinical examinations. Am J Pharm Educ (2011) 0.86
A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation. J Pharm Pharmacol (2002) 0.85
Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci (2004) 0.82
Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem. J Pharm Sci (2010) 0.81
A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biol Pharm Bull (2009) 0.79
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res (2007) 0.79
Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J Pharm Sci (2002) 0.79
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. Brain Res (2002) 0.79
Reliability of evaluation for communication competency in pharmaceutical objective structured clinical examination (OSCE). Yakugaku Zasshi (2009) 0.78
Evaluation of Bayesian predictability of vancomycin concentration using population pharmacokinetic parameters in pediatric patients. Drug Metab Pharmacokinet (2005) 0.78
Prostaglandin E2 rescues cortical neurons from amyloid beta protein-induced apoptosis. Brain Res (2003) 0.78
Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. Am J Cardiovasc Drugs (2012) 0.77
Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide. Biopharm Drug Dispos (2014) 0.77
Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: oral clearance. J Pharm Sci (2003) 0.77
Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis. Anticancer Res (2005) 0.76
Changes in HLA-DR expression, cytokine production and coagulation following endotoxin infusion in healthy human volunteers. Int Immunopharmacol (2008) 0.76
Pharmacokinetic/pharmacodynamic modeling for concentration-dependent bactericidal activity of a bicyclolide, modithromycin. J Pharm Sci (2014) 0.76
Population Pharmacodynamic Model for Bayesian Prediction of Myelosuppression Profiles Based on Routine Clinical Data after Gemcitabine and Carboplatin Treatment. Pharmacology (2016) 0.75
Pharmacokinetic prediction for intravenous beta-lactam antibiotics in pediatric patients. J Pharm Sci (2007) 0.75
Building a bridge of trust: collaborative assessment with a person with serious mental illness. J Pers Assess (2012) 0.75
Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer. Biol Pharm Bull (2014) 0.75
Bootstrap method-based estimation of the minimum sample number for obtaining pharmacokinetic parameters in preclinical experiments. J Pharm Sci (2010) 0.75
Possible Opioid Shopping and Its Correlates. Clin J Pain (2017) 0.75
Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion. Anticancer Res (2005) 0.75
Social factors of mental disorder and suicide in Japan-for understanding circumstance of suicides in each prefecture-. Yakugaku Zasshi (2013) 0.75
Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state. J Pharm Pharmacol (2003) 0.75
Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer. Biol Pharm Bull (2017) 0.75